We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 1-20 of 1,905 results
  1. Effectiveness of Simvastatin Versus Gemfibrozil for Primary Prevention of Cardiovascular Events: A Retrospective Cohort Study of 223,699 Primary Care Patients

    Background and Objective

    Evidence of the effectiveness of statins compared with fibrates for primary prevention of cardiovascular events is limited....

    Joseph E. Blais, Xuxiao Ye, ... Esther W. Chan in Clinical Drug Investigation
    Article 14 October 2022
  2. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil

    Background and Objective

    Early investigations into drug–drug interactions (DDIs) involving cytochrome P450 2C8 (CYP2C8) have highlighted the...

    Katsumi Iga, Akiko Kiriyama in Clinical Pharmacokinetics
    Article 03 November 2023
  3. Gemfibrozil

    Article 21 August 2021
  4. Single-Dose Pharmacokinetics of Ozanimod and its Major Active Metabolites Alone and in Combination with Gemfibrozil, Itraconazole, or Rifampin in Healthy Subjects: A Randomized, Parallel-Group, Open-Label Study

    Introduction

    The aims of this study were to characterize the single-dose pharmacokinetics (PK) of the major active metabolites of ozanimod, CC112273...

    Jonathan Q. Tran, Pei** Zhang, ... Maria Palmisano in Advances in Therapy
    Article Open access 28 August 2020
  5. Gemfibrozil/pegaspargase

    Article 18 January 2020
  6. Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers

    Background and Objective

    Tucatinib is approved for treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer....

    Ariel Topletz-Erickson, Anthony Lee, ... Christopher J. Endres in Clinical Pharmacokinetics
    Article Open access 06 August 2022
  7. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist

    Background and objective

    Cilofexor is a selective farnesoid X receptor (FXR) agonist in development for the treatment of nonalcoholic steatohepatitis...

    Islam Younis, Elijah Weber, ... Ahmed A. Othman in Clinical Pharmacokinetics
    Article Open access 11 March 2023
  8. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug–Drug–Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole

    Background

    Drug–drug interactions (DDIs) and drug–gene interactions (DGIs) pose a serious health risk that can be avoided by dose adaptation. These...

    Denise Türk, Nina Hanke, ... Thorsten Lehr in Clinical Pharmacokinetics
    Article Open access 25 May 2019
  9. Comparative efficacy of pharmacological agents on reducing the risk of major adverse cardiovascular events in the hypertriglyceridemia population: a network meta-analysis

    Background

    Hypertriglyceridemia (HTG) is considered an independent risk factor for major adverse cardiovascular events (MACE).

    Methods ...
    Yan-yan Qi, Li Yan, ... Song-tao An in Diabetology & Metabolic Syndrome
    Article Open access 29 January 2021
  10. Multiple drugs

    Article 06 April 2024
  11. Fenofibrate

    Article 14 October 2023
  12. Multiple drugs

    Article 09 December 2023
  13. Role of fenofibrate in multiple sclerosis

    Multiple sclerosis (MS) is the most frequent inflammatory and demyelinating disease of the central nervous system (CNS). The underlying...

    Ahmad A. Abulaban, Hayder M. Al-kuraishy, ... Gaber El-Saber Batiha in European Journal of Medical Research
    Article Open access 09 February 2024
  14. Pharmacokinetic Drug–Drug Interaction of Apalutamide, Part 1: Clinical Studies in Healthy Men and Patients with Castration-Resistant Prostate Cancer

    Background and Objectives

    Two phase I studies assessed the drug–drug interaction potential of apalutamide as a substrate and perpetrator.

    ...
    Ignacio Duran, Joan Carles, ... Caly Chien in Clinical Pharmacokinetics
    Article 27 April 2020
Did you find what you were looking for? Share feedback.